The flexible C-terminal hypervariable region distinguishes K-Ras4B, an important proto-
oncogenic GTPase, from other Ras GTPases. This unique lysine-rich portion of the protein …

To achieve drug release from polymer prodrug nanoparticles, the drug‐polymer linker must
be accessible for cleavage to release the drug, which can occur under certain physiological …

KRAS mutations are the most common oncogenic mutations in lung adenocarcinoma in
Black Americans. Polyisoprenylated Cysteinyl amide Inhibitors (PCAIs) constitute a group of …

The malignant potential of Non-Small Cell Lung Cancer (NSCLC) is dependent on cellular
processes that promote metastasis. F-actin organization is central to cell migration, invasion …

Prognoses for TNBC remain poor due to its aggressive nature and the lack of therapies that
target its “drivers”. RASA1, a RAS-GAP or GTPase-activating protein whose activity inhibits …

Simple Summary Polyunsaturated fatty acids (PUFAs) and non-steroidal anti-inflammatory
drugs (NSAIDs) have limited anticancer capacities when used alone. We examined whether …

Pancreatic cancer is characterized by K-Ras mutations in over 90% of the cases. The
mutations make the tumors aggressive and resistant to current therapies resulting in very …

Background: Non-small cell lung cancers (NSCLC) harboring mutation-induced
dysregulation of Ras signaling present some of the most difficult-to-manage cases, since …

Metastatic castration-resistant prostate cancer (mCRPC) is the most aggressive and deadly
form of prostate cancer. It is characterized by the overexpression of epidermal growth factor …

Aberrant activation of monomeric G-protein signaling pathways drives some of the most
aggressive cancers. Suppressing these hyperactivities has been the focus of efforts to obtain …